Your browser doesn't support javascript.
loading
Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma.
Franco, Abigail I; Eastwick, Gary; Farah, Ramsay; Heyboer, Marvin; Lee, Mijung; Aridgides, Paul.
Afiliación
  • Franco AI; St. Joseph's Hospital Health Center, 301 Prospect Avenue, Syracuse, NY 13203, USA.
  • Eastwick G; Upstate University Hospital, 750 E. Adams Street, Syracuse, NY 13210, USA.
  • Farah R; Upstate University Hospital, 750 E. Adams Street, Syracuse, NY 13210, USA.
  • Heyboer M; Upstate University Hospital, 750 E. Adams Street, Syracuse, NY 13210, USA.
  • Lee M; Upstate University Hospital, 750 E. Adams Street, Syracuse, NY 13210, USA.
  • Aridgides P; Upstate University Hospital, 750 E. Adams Street, Syracuse, NY 13210, USA.
Case Rep Dermatol Med ; 2018: 2354146, 2018.
Article en En | MEDLINE | ID: mdl-29682362
ABSTRACT
We present a case report of a male with multifocal and extensive basal cell carcinoma. Due to extremely large size and deep tumor infiltration, he was not a surgical candidate. Combined modality treatment of fractionated radiation with concurrent vismodegib was chosen. Concurrent treatment was previously reported in the palliative and recurrent setting. This is the first case of concurrent vismodegib and radiation therapy for upfront definitive management. The patient experienced complete response in all treated lesions.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Case Rep Dermatol Med Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Case Rep Dermatol Med Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos
...